Viewing Articles By Martin Joseph

Despite allocating an increasing proportion of sales revenue to research and development the pharmaceutical industry has largely failed to increase the average annual number of new drug introductions. Furthermore, development attrition rates have changed little over the last 25 years. If we make assumptions that the average attrition rate for biologics is somewhat lower than for traditional small molecules, we might conclude that the attrition rate for the latter has in fact worsened. Why is this?